Lantern Pharma Inc. Common Stock earnings per share and revenue
On Nov 12, 2025, LTRN reported earnings of -0.39 USD per share (EPS) for Q3 25, beating the estimate of -0.47 USD, resulting in a 18.65% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.57% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.46 USD, with revenue projected to reach -- USD, implying an increase of 17.95% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Lantern Pharma Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Lantern Pharma Inc. Common Stock reported EPS of -$0.39, beating estimates by 18.65%, and revenue of $0.00, 0% as expectations.
How did the market react to Lantern Pharma Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -0.57%, changed from $3.48 before the earnings release to $3.46 the day after.
When is Lantern Pharma Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 25, 2026.
What are the forecasts for Lantern Pharma Inc. Common Stock's next earnings report?
Based on 3
analysts, Lantern Pharma Inc. Common Stock is expected to report EPS of -$0.46 and revenue of -- for Q4 2025.